AstraZeneca showcased significant progress at the 2025 ESMO Congress, presenting data from over 95 abstracts that highlight advancements in its oncology portfolio, including nine approved medicines and nine potential new treatments.

The company shared promising results from trials on innovative therapies such as saruparib for prostate cancer, torvu-sam for ovarian cancer, and rilvegostomig for non-small cell lung cancer, emphasizing its commitment to personalized cancer treatment.

AstraZeneca's presentations underscored its dedication to early intervention strategies and improving patient outcomes through cutting-edge clinical research across various cancer types.

Safety data for ENHERTU revealed risks including neutropenia, nausea, fatigue, and serious adverse events like interstitial lung disease (ILD) and pneumonitis, with some fatalities reported, highlighting the importance of monitoring.

Additional safety information emphasized the incidence of ILD and pneumonitis, which occur in approximately 10-12% of patients depending on the cancer, and the need for vigilant monitoring and dose adjustments.

Key clinical trials such as DESTINY-Breast11 and DESTINY-Breast05 demonstrated promising outcomes for ENHERTU in early and metastatic breast cancer, including post-neoadjuvant settings.

Other notable studies like TROPION-Breast02 and POTOMAC showed the potential of Datroway and Imfinzi in treating metastatic triple-negative breast cancer and early bladder cancer, respectively.

Results from the MATTERHORN trial are expected to reveal survival benefits of combining Imfinzi with FLOT chemotherapy in gastric and gastroesophageal cancers.

Leadership highlighted the strength of AstraZeneca’s pipeline, focusing on delivering earlier, transformative treatments to improve outcomes across multiple cancer types.

AstraZeneca continues to expand its targeted therapy portfolio through collaborations with Daiichi Sankyo on ENHERTU and DATROWAY, Merck on olaparib, and HUTCHMED on savolitinib, reinforcing its strategic alliances.

The company's overarching goal remains to redefine cancer care through persistent innovation, aiming ultimately to eliminate cancer as a cause of death globally.